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The anti-human immunodeﬁciency virus (HIV) drug efavir-
enz (EFV) alters mitochondrial function in cultured neurons
and glial cells. Nitric oxide (NO) is a mediator of mitochon-
drial dysfunction associated with HIV central nervous system
symptoms. We show that EFV promotes inducible nitric
oxide synthase (iNOS) expression in cultured glial cells and
generated NO undermines their mitochondrial function, as
inhibition of NOS partially reverses this effect. EFV inhibits
mitochondrial Complex I in both neurons and glia; however,
when the latter cells are treated for longer periods, other mi-
tochondrial complexes are also affected in accordance with
the increased NO production. These ﬁndings shed light on
the mechanisms responsible for the frequent EFV-associated
neurotoxicity.
Keywords. efavirenz; electron transport chain; HIV; mito-
chondria; nitric oxide; NNRTI; central nervous system.
The nonnucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz (EFV) is among the most widely prescribed anti-
human immunodeﬁciency virus (HIV) drugs. Although con-
sidered safe, the majority of patients experience a variety of
neuropsychiatric side effects that can require therapy discontin-
uation [1]. Moreover, its long-term use has been linked to neu-
rocognitive impairment [2].This is of concern given that 50% of
HIV(+) patients undergo a gradual cognitive deterioration
known as HIV-associated neurocognitive disorder (HAND)
whose pathogenesis has been linked to the neurotoxicity of
antiretrovirals [3–5]. The mechanism behind EFV-produced
central nervous system (CNS) toxicity is unclear, but mounting
in vivo and in vitro evidence points to an alteration of brain
energy homeostasis [6, 7]. Recently, we have shown that EFV
affects the bioenergetics and viability of cultured neurons and
glial cells by acute mitochondrial interference. The repercus-
sions of this action vary; compensatory mechanisms were acti-
vated in glial cells—upregulated glycolysis and augmented
intracellular adenosine triphosphate (ATP) levels—but not in
neurons, rendering the latter cells more vulnerable to the effects
of EFV and other stressors [8]. The effects of EFV were poten-
tiated by exogenous nitric oxide (NO), a neuromodulator and
regulator of mitochondrial function. NO is also a crucial proin-
ﬂammatory CNS mediator associated with the pathogenesis of
different neuroinﬂammatory and neurodegenerative condi-
tions. Mammalian cells generate NO as a by-product of NO
synthase (NOS) activity. While neurons express neuronal NOS
(nNOS), a constitutive isoform that synthesizes moderate
amounts of NO, glial cells express inducible NOS (iNOS),
which generates major NO amounts [9]. There is clear experi-
mental and clinical evidence to implicate NO in the CNS symp-
toms of HIV. Animal studies suggest that iNOS-derived NO is a
major mediator of HIV-1 gp41 neurotoxicity. More importantly,
increased production of NO has been related to HIV-associated
dementia, whose severity has been correlated with iNOS expres-
sion, suggesting an association with the neuroinﬂammatory mi-
lieu surrounding HIV infection [10–12]. The present study
evaluates the role of endogenous NO in the mitochondrial effects
of EFV on neurons and glial cells.
MATERIAL AND METHODS
Reagents and Treatments
Unless otherwise stated, chemicals were from Sigma-Aldrich.
EFV (Sequoia Research Products) was dissolved in methanol
(3 mg/mL), which was employed as a vehicle control and did
not inﬂuence any of the parameters studied. To evaluate the in-
ﬂuence of NO synthase activity, cells were treated (24 hours)
with “lipopolysaccharides (LPS) cocktail,” composed of Escher-
ichia coli endotoxin (LPS, 1 µg/mL), interferon-γ (50 U/mL) and
tumor necrosis factor-α (20 ng/mL), with or without the non-
speciﬁc NOS inhibitor L-NG-nitroarginine methyl ester (L-
NAME 50 µM, Cayman Chemical). 3-morpholinosydnonimine
(SIN-1 33 µM) was employed as a positive control for peroxyni-
trite assessment and (Z)-1-[2-aminoethyl)-N-(2-ammonioethyl)
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amino]diazen-1-ium-1,2-diolate (DETA-NO, 0.3 or 0.5 mM) as
an external NO donor (Supplementary Figure 1).
Cell Culture
Cell cultures were maintained and treated as described previ-
ously [8]. All experiments were performed on human neuro-
blastoma (SH-SY5Y) and glioma (U-251MG) cell lines, with
conﬁrmatory analysis on primary rat cortical astrocytes and
neurons (isolated in accordance with European Community
guidelines for the use of animal experimental models, approved
by the Ethics Committee of the University of Valencia).
Protein Extraction and Western Blot Analysis of nNOS and iNOS
Treatments (6 and 24 hours), whole-cell protein extraction, and
Western blot (WB) were performed as described elsewhere [8].
Primary antibodies: mouse monoclonal anti-iNOS (1:1000; BD
Biosciences) and anti-nNOS (1:2500; BD Biosciences), and
anti-actin rabbit polyclonal (1:1000; Sigma-Aldrich). Secondary
antibodies: horseradish peroxidase–conjugated goat anti-mouse
(1:2000) and anti-rabbit immunoglobin-G (1:5000), both from
Thermo Scientiﬁc.
Fluorescence Microscopy and Static Cytometry
Fluorescence microscopy was performed using an Olympus
IX81 microscope with “ScanR” static cytometry software ver-
sion 2.03.2. U-251MG (3 × 104 cells/cm2), SH-SY5Y (1.5 × 104
cells/cm2), primary neurons (2.5 × 105 cells/cm2), and astro-
cytes (4 × 104 cells/cm2) were treated (48-well plates, 6 or 24
hours), and Hoechst 33342 (1 µM) to mark nuclei and speci-
ﬁc ﬂuorochromes (2.5 µM except for DHR123, 25 µM) added
for the last 30 minutes. Subsequently, cells were Hank’s ba-
lanced salt solution (HBSS)–washed and 16–20 live-cell images/
well recorded. Intracellular NO and peroxynitrite (ONOO−),
mitochondrial superoxide, and mitochondrial membrane po-
tential (ΔΨm) were assessed using diaminorhodamine-4M
AM (DAR-4M AM), dihydrorhodamine 123 (DHR123), both
from Sigma Aldrich, and MitoSOX and tetramethylrhodamine
methyl ester (TMRM), both from Molecular Probes, Invitrogen
respectively.
Electrochemical Measurement of Oxygen Consumption
After 6 hours treatment, cells (4 × 106) were placed in a gas-tight
chamber (1 mL HBSS, 37°C) and their oxygen (O2) consump-
tion monitored with a Clark-type O2 electrode (Rank Brothers)
with the Duo.18 data acquisition device (WPI).
Spectrophotometric Analysis of the Activity of the Oxidative
Phosphorylation Complexes
Cell homogenates (1.5 × 106 U-251MG and 3.0 × 106 SH-SY5Y)
were obtained with 0.2 mL SETH buffer (250 mM sucrose, 2 mM
ethylenediaminetetraacetic acid, 10 mM Tris-HCl, 100 U/L
heparin, pH 7.4) after sonication (ice-cold water, 3 × 10 seconds
with 30 seconds rests) and centrifugation (8000 g, 10 minutes).
Protein concentration was determined by the Bradford method.
Reduced nicotinamide adenine dinucleotide (NADH): coenzyme
Q1 oxidoreductase activity (CI) was evaluated according to the
rate of NADH-dependent coenzyme Q1 reduction (340 nm).
Succinate dehydrogenase activity (CII) was assessed according
to the decrease in absorbance due to the reduction of 2,6-
dichlorophenolindophenol (600 nm). Cytochrome c reduction
from decylubiquinone (DBH2) (550 nm) was calculated to eval-
uate ubiquinol: cytochrome c oxidoreductase activity (CIII) and
cytochrome c oxidase activity (CIV) was assessed by calculating
the decrease in absorbance due to the oxidation of previously
reduced (with sodium borohydride) cytochrome c (550 nm).
Absorbance was detected using TECAN inﬁnite M200
spectrophotometer.
Lactate Determination
Lactate in the extracellular medium was evaluated using the
Lactate Assay Kit (BioVision) and a Multiskan plate reader
spectrophotometer (Thermo Labsystems) [8].
Statistics and Data Representation
Data (% of control—untreated cells considered 100%) were
analyzed (GraphPad Prism v.5 software) with 1-way ANOVA
followed by a Newman-Keuls post hoc test (control conditions
independently analyzed by Student t-test). All measurements
were performed in duplicate, repeated at least 3 times and
data represented as mean ± standard error of margin of these
independent experiments.
RESULTS
EFV-induced NOS Activation in Glial Cells
Cells were treated with EFV (10 or 25 µM) or an LPS cocktail
(a mixture of proinﬂammatory molecules that induce iNOS)
for 6 or 24 hours. WB analysis revealed that EFV increased
the expression of iNOS in glial cells (U-251MG), at 25 µM. Ex-
pression levels were similar at 6 and 24 hours, and reﬂected
those induced by the LPS cocktail (24 hours). Neither EFV
nor LPS cocktail activated nNOS in neurons (SH-SY5Y) (Fig-
ure 1A). Assessment of NO by ﬂuorescence microscopy con-
ﬁrmed the results of iNOS expression, as EFV (10 and 25
µM) increased NO levels in glial cells but not in neurons.
This effect was conﬁrmed in primary cortical rat cell cultures,
which ruled out the possibility of it being due to the cancerous
nature of the cell lines employed (Figure 1B).
EFV-induced NO Interferes with Mitochondrial Function and
Bioenergetics in Glial Cells
We evaluated 3 characteristic parameters (O2 consumption, mi-
tochondrial reactive oxygen species [ROS] generation, and
ΔΨm) in the presence of the nonselective NOS inhibitor, L-
NAME (50 µM). Inhibition of NO synthesis alone did not mod-
ify the respiration rate in either cell type (data not shown). Glial
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Figure 1. Effect of efavirenz (EFV) on nitric oxide (NO) production. Human cell lines U-251MG (glioblastoma) and SH-SY5Y (neuroblastoma) and primary
cultures of rat cortical astrocytes and neurons were exposed to EFV (10 or 25 µM) or lipopolysaccharide (LPS) cocktail for 6 or 24 hours. A, inducible
nitric oxide synthase (iNOS) (U-251MG) and neuronal nitric oxide synthase (nNOS) (SH-SY5Y) expression were analyzed by Western blot. Representative
images (24 hours) and summary of the densitometry results of several independent experiments are shown (6- and 24-hour treatment, expressed as
mean ± standard error of the mean (SEM), n = 3–4). B, Intracellular NO content (U-251MG, SH-SY5Y, and primary cell cultures) was assessed by ﬂuores-
cence microscopy using the ﬂuorochrome DAR-4M AM. Representative life-cell images (10×) (U-251MG and SH-SY5Y) showing nuclei (in blue, stained with
Hoechst 33342) and the red ﬂuorescent signal coming from NO (24 hours-treatment), and summary of the quantiﬁcation of the mean ﬂuorescence of 4
independent experiments (mean ± SEM, n = 4) after 6 and 24 hours of treatment. Data were expressed as comparison with those of untreated cells (con-
sidered 100%) and analyzed by a 1-way analysis of variance (ANOVA) multiple comparison test followed by Newman–Keuls test; signiﬁcance versus vehicle
(Veh) *P < .05, **P < .01, ***P < .001. Data for LPS cocktail were independently analyzed by Student t test, #P < .05, ##P < .01, ###P < .001.
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Figure 2. Interference of nitric oxide (NO) with mitochondrial function and bioenergetics. U-251MG (glioblastoma) and SH-SY5Y (neuroblastoma) cells
were exposed to efavirenz (EFV) (10 or 25 µM) or a cotreatment of 25 µM EFV + 50 µM LNG-nitroarginine methyl ester (L-NAME) for 6 or 24 hours: A, O2
consumption in intact cells (Clark-type O2 electrode); quantiﬁcation of data showing the rate of O2 consumption in the absence (vehicle [Veh]) and presence
of EFV or EFV+L-NAME after 6 hours treatment. L-NAME alone did not have any effect on O2 consumption (not shown). B, Determination of superoxide
production (mean MitoSOX ﬂuorescence) after 6 hours treatment. C, Determination of mitochondrial membrane potential (relative TMRM ﬂuorescence) after
6 hours treatment. D, Analysis of extracellular lactate levels in U-251MG cells after 24 hours treatment. E, Impact of EFV on the mitochondrial electron
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cells cotreated with EFV+L-NAME (6 hours) manifested a
smaller decrease in the O2 consumption than those treated
with EFV alone (Figure 2A), whereas no such differences were
observed in neurons. Mitochondrial superoxide generation re-
vealed similar results (Figure 2B), showing that as the decrease
in O2 consumption, the enhanced ROS generation in EFV-
treated glial cells was partially due to the increased NO levels.
However, no Δψm recovery was observed in either neurons or
glial cells when treated with L-NAME (Figure 2C), thus indicat-
ing that the EFV-induced reduction of Δψm was NO-indepen-
dent. Moreover, the stimulatory effect of EFV on glycolysis in
glial cells [8] was also partially reversed when NO synthesis
was impaired, suggesting NO participation in this bioenergetic
action of EFV (Figure 2D).
EFV Speciﬁcally Alters Mitochondrial Electron Transport Chain:
Effect on CI Activity and NO Interference
Recently, EFV has been shown to compromise mitochondrial
respiration in both glial cells and neurons [8]. In the present
study, 1-hour treatment with EFV produced a major and con-
centration-dependent decrease in CI activity in glial cells similar
to the CI pharmacological inhibitor rotenone (ROT, 10 µM).
This effect was enhanced when treatment was extended to 6
hours; furthermore, a modest, but statistically signiﬁcant, de-
crease of CIII activity was detected (Figure 2E ). EFV-exposed
neurons also manifested a concentration- and time-dependent
(1 and 6 hours) decrease in CI activity, but without alterations
with respect to CIII (Figure 2E ). As expected, NO interfered
with CIV, as shown by the fact that exogenous NO (DETA-
NO, 1 and 6 hours) diminished CIV activity in a time-
dependent manner in both neurons and glial cells. Twenty-
four-hour EFV exposure led to a signiﬁcant decrease in CIV
activity in glial cells but not in neurons, which is in line with
our results regarding EFV-induced NO generation in glial
cells only. The participation of NO was conﬁrmed by the ﬁnd-
ing that the inhibitory effect of EFV on CIV was prevented
when glial cells were coincubated with EFV (25 µM) + L-
NAME (50 µM).We found no increase of intracellular peroxy-
nitrite levels in glial cells at any of the time points studied
(Supplementary Figure 2). Inside live cells, DHR123 is oxi-
dized to the ﬂuorescent product rhodamine 123, which due
to its cationic properties, localizes in mitochondria. However,
the nonﬂuorescent compound DHR123 is not selectively
targeted to the mitochondrial compartment; therefore, al-
though DHR123 detects changes in intracellular peroxynitrite
content, it may be not so sensitive to detect small changes
occurring intramitochondrially.
DISCUSSION
Our results demonstrate that clinically relevant concentrations
of EFV induce the expression of iNOS in glial cells and that NO
thus generated participates in the inhibitory mitochondrial ef-
fects of EFV. It is well known that NO interferes with mitochon-
drial function and that the extent of this effect depends on the
NO amount. Moderate quantities, like those continuously gen-
erated by nNOS, modulate cell respiration by competing with
O2 at CIV of the mitochondrial electron transport chain
(ETC) [13]. Larger amounts, like those produced following
the expression of iNOS by inﬂammatory mediators, result in
persistent damage of CIV and other ETC complexes, in which
the role of NO is complex [13]. The present results show that
incubation with EFV for a short period (1 hour) reduces mito-
chondrial O2 consumption in both glial cells and neurons in
what seems to be the consequence of a direct and immediate in-
hibitory effect on CI. This ﬁnding is in line with previously pub-
lished evidence of such an effect in isolated rat mitochondria
[14]. Longer periods further enhance CI inhibition in both
glial cells and neurons; however, in glial cells, other mitochon-
drial complexes—CIII and CIV—were also affected (at 6 and 24
hours, respectively), an effect that coincides with the timeframe
of increased NO production in these cells only. Indeed, this later
effect of EFV on CIV involves the participation of NO as shown
by its prevention upon nonselective NOS inhibition. Moreover,
such inhibition partially reversed EFV actions on mitochondrial
respiration and superoxide generation in glial cells, but not in
neurons, which clearly implies a speciﬁc iNOS involvement in
the actions of this anti-HIV drug in glial cells. The present re-
sults, which expand our previous ﬁndings [8], are partially in
accordance with 1 report on EFV-treated mice describing inhi-
bition of CIV activity in different brain areas [15]; however, in
this work CI was not altered, which makes further studies of this
mitochondrial effect necessary.
We also demonstrate that iNOS-derived NO enhances the
upregulation of glycolysis that follows EFV-induced mitochon-
drial interference in glial cells. There are important differences
Figure 2 continued. transport chain (ETC): individual analysis of ETC complex activity. U-251MG and SH-SY5Y cells were exposed to EFV (10 and 25 µM)
for 1 and 6 hours and the individual activity of complexes I–IV was studied. Complex IV activity was also assessed at 24 hours of incubation. Rotenone (ROT)
10 µM was employed as a speciﬁc inhibitor of coenzyme Q1 oxidoreductase activity (CI), and potassium cyanide (KCN) 200 µM and (Z)-1-[2-aminoethyl)-N-
(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO) 0.5 mM (U-251MG) or 0.3 mM (SH-SY5Y) were used as inhibitors of cytochrome c oxidase
activity (CIV). In all panels of this ﬁgure, data were compared to those of untreated cells (considered 100%), represented as mean ± standard error of
the mean (SEM) of several independent experiments (n = 3–5) and analyzed by a 1-way analysis of variance (ANOVA) multiple comparison test followed
by Newman–Keuls test, signiﬁcance versus vehicle *P < .05, **P < .01, ***P < .001. Data for Rotenone, KCN, and DETA-NO were independently analyzed by
means of a Student t test; #P < .05, ##P < .01, ###P < .001. +P < .05 and ++P < .01 represent the signiﬁcance of the data obtained with EFV 25 µM versus EFV
25 µM+ L-NAME (Student t test).
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between the bioenergetics of glial cells and neurons. The former
are highly glycolytic and capable of maintaining ATP levels,
making them more resistant than neurons to mitochondrial in-
sults and bioenergetic stress. Importantly, a scenario of glial cell
survival and neuronal degeneration with mitochondrial dysfunc-
tion has been associated with neurocognitive disorders, including
HIV-associated dementia. Finally, our results, which implicate
NO in the mitochondrial effects of EFV, shed some light on
the mechanisms of the CNS side effects of this drug. It is plausi-
ble that EFV-induced NOmodulates the interplay between brain
cells, as NO generated within glial cells may act on adjacent neu-
rons and inﬂuence their mitochondria and other cellular path-
ways. It could also be argued that some of the neuropsychiatric
symptoms that appear early after EFV therapy initiation some-
times overlap with a degree of neuroinﬂammation, and that
EFV, alone or in combination with the NO produced by glial
cells, could exacerbate this situation. Given that HIV treatment
is for life, further research is vital to evaluate whether EFV-
induced NO plays a role in the long-term development of the
neuroinﬂammatory CNS symptoms of HIV, including HAND.
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